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Abstract
Background: Symptoms of dyspepsia significantly disrupt patients' lives and reliable methods of
assessing symptom status are important for patient management. The aim of the current study was
to document the psychometric characteristics of the Gastrointestinal Symptom Rating Scale
(GSRS) and the Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD) in Afrikaans,
German, Hungarian, Italian, Polish and Spanish patients with dyspepsia.
Methods: 853 patients with symptoms of dyspepsia completed the GSRS, the QOLRAD, the 36-
item Short-Form Health Survey (SF-36) and the Hospital Anxiety and Depression scale.
Results: The internal consistency reliability of the GSRS was 0.43–0.87 and of the QOLRAD 0.79–
0.95. Test-retest reliability of the GSRS was 0.36–0.75 and of the QOLRAD 0.41–0.82. GSRS
Abdominal pain domain correlated significantly with all QOLRAD domains in most language
versions, and with SF-36 Bodily pain in all versions. QOLRAD domains correlated significantly with
the majority of SF-36 domains in most versions. Both questionnaires were able to differentiate
between patients whose health status differed according to symptom frequency and severity.
Conclusion: The psychometric characteristics of the different language versions of the GSRS and
QOLRAD were found to be good, with acceptable reliability and validity. The GSRS and QOLRAD
were found to be useful for evaluating dyspeptic symptoms and their impact on patients' daily lives
in multinational clinical trials.
Published: 31 January 2008
Health and Quality of Life Outcomes 2008, 6:12 doi:10.1186/1477-7525-6-12
Received: 21 August 2007
Accepted: 31 January 2008
This article is available from: http://www.hqlo.com/content/6/1/12
© 2008 Kulich et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 12
(page number not for citation purposes)
Health and Quality of Life Outcomes 2008, 6:12 http://www.hqlo.com/content/6/1/12Background
The definition and characterization of dyspepsia continue
to challenge clinical investigators. At the Rome II consen-
sus conference held in 1999, the recommended definition
of dyspepsia was 'pain or discomfort centred in the upper
abdomen' [1,2]. Yet, symptoms such as heartburn, nau-
sea, post-prandial fullness, early satiety or bloating may
also be present [3-7]. Recent guidelines suggest that gas-
troesophageal reflux disease (GER) is the likely diagnosis
if heartburn is the only presenting symptom or the pre-
dominant symptom [8-10].
The label 'functional dyspepsia' is often used interchange-
ably with that of 'dyspepsia', but actually refers to patients
whose dyspepsia has been investigated and has no known
structural or biochemical cause [8,11]. Studies on the
prevalence of dyspepsia in primary care originate mainly
from a few developed countries, where the disorder
accounts for 1–4% of all primary care consultations
[6,12,13]. Estimates of the prevalence of dyspepsia in the
adult general population are noticeably higher, ranging
from 20–40% [7,11]. The frequency of medical visits for
dyspepsia has been found to increase with increasing age
[14], and with increasing severity of dyspeptic symptoms
[15].
Dyspepsia symptoms impair patients' daily functioning
[16-21]. The symptom-driven nature of patient manage-
ment places particular importance on a reliable estima-
tion of symptom status. Hence, the assessment of how
symptoms of dyspepsia affect patients' lives provides
important information about the patients' health status
and their perception of the treatment regime [22]. Moreo-
ver, this information helps enable clinicians to tailor treat-
ment to the individual patient's needs.
Despite increasing interest in evaluating the impact of dys-
pepsia symptoms on patients' daily lives, measuring this
impact in clinical trials can be problematic due to a pau-
city of validated instruments [23]. Furthermore, clinical
trials are increasingly being conducted as multinational
studies. This requires the availability of validated non-
English language versions of the instrument to be used.
Three patient-reported outcomes (PRO) instruments have
been validated in patients with dyspepsia in clinical trials:
the Severity of Dyspepsia Assessment (SODA) [24], the
Nepean Dyspepsia Index (NDI) [25] and the Dyspepsia
Symptom Severity Index (DSSI) [26]. However, all three
instruments have only been validated as English-language
versions. A further concern is that the NDI has not been
validated for treatment effects, and the SODA was vali-
dated in a non-representative patient population compris-
ing 96% men [24].
To be a viable measure of treatment outcome in clinical
trials, PRO instruments need to be extensively docu-
mented to meet scientific standards [27,28] and to satisfy
regulatory criteria, particularly with regard to claims for
labelling and promotion [28,29]. The regulatory criterion
is twofold: linguistic cross-cultural adaptation, and psy-
chometric documentation. The US Food and Drug
Administration (FDA) has recently issued a draft guidance
on PRO measures [28]. In line with these guidelines,
instruments need to show reliability, validity and an abil-
ity to detect change.
This report aims to document the psychometric character-
istics of two PRO instruments, the Gastrointestinal Symp-
tom Rating Scale (GSRS) and the Quality of Life in Reflux
and Dyspepsia questionnaire (QOLRAD), in patients with
dyspepsia. The GSRS and the QOLRAD were developed in
US English. Several translations of both questionnaires
have been psychometrically validated previously in
patients with GERD [30-35]. In addition, English versions
of the questionnaires have been used in dyspeptic popu-
lations (AstraZeneca, data on file). For the present report,
a series of studies was undertaken in patients with dyspep-
sia in South Africa, Germany, Hungary, Italy, Poland and
Spain. To enable comparisons between the various coun-
tries studied, results from all countries are presented here
together in the current paper.
Methods
Patients
Consecutive patients with predominant symptoms of dys-
pepsia attending gastroenterology clinics between Decem-
ber 2000 and August 2003 were included in the study. In
Germany and Spain, patients were also included from pri-
mary care. Dyspepsia was defined as persistent and/or
recurrent pain or discomfort centred in the upper abdo-
men. Inclusion criteria required a history of episodes of
dyspepsia for 6 months or longer, and episodes of dyspep-
sia on at least 1 day during the previous 7 days. The diag-
nosis based on the patient reports, and was verified at the
discretion of the investigator. Where the diagnosis was
uncertain, patients were not included. No physical exam-
inations were performed. The following were exclusion
criteria: GERD, irritable bowel syndrome, peptic ulcer dis-
ease, dementia or any other significant medical, psychiat-
ric or surgical disease. Patients receiving daily treatment
with acetyl salicylic acid or other nonsteroidal anti-
inflammatory drugs were also excluded. Patients had to be
able to complete the PRO instruments unaided, as no
proxy assessment or interpreter was allowed. The admin-
istration of the questionnaires took place at visit 1 before
any medical procedures were performed. Patients who
were judged to be in stable phase were scheduled for a sec-
ond visit. The second visit occurred 7 days after visit 1. The
study was approved by local ethics committees in allPage 2 of 12
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study. Good Clinical Practice was followed and the
patients were free to discontinue participation in the study
at any time.
Demographic and clinical variables
Clinicians recorded patient demographics (including age,
sex, ethnicity, and marital and employment status), med-
ical history (including history of gastrointestinal diseases)
and frequency of dyspepsia symptoms (number of days
with episodes during the last 7 days). Investigators also
assessed the severity of patients' dyspepsia symptoms by
asking the patients and then recording the answer using a
four-point graded scale (0 = none: no symptoms; 1 =
mild: awareness of sign or symptom, but easily tolerated;
2 = moderate: discomfort sufficient to cause interference
with normal activities; 3 = severe: incapacitating with ina-
bility to perform normal activities). All data were recorded
in a case-report form.
PRO instruments
Patients completed two disease-specific and two generic
PRO instruments: the GSRS, the dyspepsia version of the
QOLRAD, the 36-Item Short-Form Health Survey (SF-36),
and the Hospital Anxiety and Depression scale (HAD)
(except in South Africa, where patients were not given the
HAD). Questionnaires were completed in an electronic
data capture (EDC) device (Apple Newton Pad, Apple
Computers Inc, Cupertino, CA, USA), except in South
Africa, where paper and pencil were used. The method of
using electronic patient-reported outcomes (ePRO) for
recording of symptoms and health-related quality of life
has previously been shown to improve the quality of the
data and to be well received by patients [36]. Study per-
sonnel were trained in how to use the electronic device
and how to instruct the patients in a standardized way to
minimize bias and enhance compliance.
Gastrointestinal Symptom Rating Scale (GSRS)
The GSRS is a disease-specific instrument of 15 items
combined into five symptom clusters depicting Reflux,
Abdominal pain, Indigestion, Diarrhoea and Constipa-
tion. The GSRS has a seven-point graded Likert-type scale
where 1 represents absence of troublesome symptoms
and 7 represents very troublesome symptoms. The relia-
bility and validity of the GSRS are well-documented [37],
and norm values for a general population are available
[38].
Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD)
The dyspepsia version of the QOLRAD is a disease-specific
instrument, including 25 items combined into five
dimensions: Emotional distress, Sleep disturbance, Vital-
ity, Food/drink problems and Physical/social functioning.
The questions are rated on a seven-point graded Likert
scale; lower values indicate a more severe impact on daily
functioning. The reliability and validity of the QOLRAD
have been documented in patients with dyspepsia [39].
Previous studies have shown that a difference of approxi-
mately 0.5 points represents a clinically relevant change
[40]. The factor structure of the QOLRAD has been repli-
cated for several language versions [41].
36-item Short-Form Health Survey (SF-36)
The SF-36 is an extensively used generic questionnaire
containing 36 items clustered into eight dimensions
(Bodily pain, General health, Mental health, Physical
functioning, Role – emotional, Role – physical, Social
functioning, Vitality). Item scores for each dimension are
coded, summed and transformed to a scale from 0 (worst
possible health status) to 100 (best possible health sta-
tus). The SF-36 is well-documented in terms of reliability
and validity in all available language versions [42,43].
This study used the acute version of the SF-36 covering a
1-week recall period [44].
Hospital Anxiety and Depression scale (HAD)
The HAD is a screening tool developed for use in medical
settings. It consists of 14 items divided into two subscales
for anxiety (seven items) and depression (seven items), in
which the patient rates each item on a four-point scale.
The higher scores indicate the presence of problems. A
cut-off of > 11 implies definite cases of anxiety or depres-
sion, a cut-off of 8–10 a probable case, and < 7 not a case.
The validity and reliability of the HAD have been reported
in several studies [45,46]. The HAD was not used in South
Africa because the Afrikaans translation was not available
at the start of the study.
All instruments have been translated and linguistically
validated according to international guidelines [47]. The
linguistic validation of a questionnaire is not a literal
translation of the original questionnaire, but the produc-
tion of a translation, which is conceptually equivalent to
the original and culturally acceptable in the country in
which the translation will be used. This translation proc-
ess includes forward- and back-translations by different,
independent translators. Several translations of the GSRS
and the QOLRAD are available, including Afrikaans, Ger-
man, Hungarian, Italian, Polish and Spanish versions,
and all have been psychometrically validated previously
in patients with GERD [30-35].
Psychometric evaluation of the GSRS and the QOLRAD
Reliability
Internal consistency refers to the extent to which the items
within each dimension are interrelated. Cronbach's alpha
is the most widely used measurement for assessing inter-
nal consistency reliability [48]. A high alpha coefficient (≥Page 3 of 12
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the same construct and supports the construct validity.
Test-retest reliability measures the stability of a score
derived from serial administrations of a measure by the
same rater. Repeated measurements are made in the same
individuals, at a time interval long enough to ensure inde-
pendence. Here, patients whose symptoms were judged to
be stable, and in whom the treatment – not study man-
dated – remained unchanged, were assessed between vis-
its 1 and 2. An intraclass correlation coefficient (ICC)
above 0.70 was considered to be acceptable [49].
Construct validity
Construct validity is concerned with whether the indicator
actually measures the underlying attribute. The construct
validity was examined by convergent, discriminant and
known-groups validity.
Convergent validity consists of showing that a postulated
dimension of the instrument correlates appreciably with
all other dimensions that theory suggests should be
related to it. Here, it was examined by: (a) correlating the
GSRS with the QOLRAD; (b) correlating the GSRS and the
QOLRAD with the SF-36 dimensions; and (c) correlating
the GSRS and the QOLRAD with the HAD (except in
South Africa) and with clinician-rated severity of dyspep-
sia symptoms. Similar dimensions in these instruments
were expected to have high correlations with each other as
shown by Pearson's product moment correlation. A
strong correlation was considered to be over 0.60, a mod-
erate between 0.30 and 0.60 and a low (very low) correla-
tion below 0.30 [50]. Low correlations were expected
between those dimensions that are theoretically unrelated
constructs, thereby testing the discriminant validity of the
instruments.
Known-groups validity consists of showing that an instru-
ment can differentiate between groups of patients whose
health status differs according to the characteristics of
patients' disease, in this case clinician-rated frequency and
severity of dyspepsia symptoms [51,52].
Statistical methods
Statistical analyses were performed using Statistical Anal-
ysis System (SAS, version 8.02) [53]. Bonferroni correc-
tion was used to adjust for the multiplicity (significance
level, P < 0.0003), corresponding to a correlation of 0.32
or above [54]. If data were missing from one or more item
in a PRO instrument, the mean of the completed items in
the same dimension was used provided that more than
half of the items in that dimension had been completed
[55]. The percentage of missing data in the GSRS and
QOLRAD, respectively, were as follows: South Africa,
2.7% and 2.7%; Germany, 6.4% and 12.7%; Hungary,
8.8% and 8.8%; Italy, 6.3% and 1.1%; Poland, 0.7% and
0.7%; Spain, 0.6% and 0.6%. In cases where more than
6% of the data were missing (Germany, Hungary and
Italy), characteristics (age, gender, duration and frequency
of dyspepsia symptoms) of patients with missing data
were compared with those who completed the question-
naires fully. There were no significant differences between
the two groups.
Results
Demographic and clinical characteristics
A total of 853 patients with dyspepsia were included in
the study. Patient demographics and clinical characteris-
tics are shown in Table 1. Patients' ages ranged from 18 to
79 years (range, mean age: 42.2–48.3 years; standard devi-
ation [SD]: 11.8–15.9 years), and the majority (61.1–
72.1%) of patients were female. Virtually all participants
were Caucasian, except in South Africa, where 89% of
patients were of mixed ethnic origins. In all countries,
more than half of patients were married (range: 59.5–
69.7%). Full-time employment was highest in Hungary
and lowest in South Africa and Spain (overall range: 41.4–
64.0%).
The majority (59.3–70.9%) of patients had moderate dys-
pepsia symptoms over the past week, except in South
Africa, where the majority (55%) had severe symptoms. In
terms of frequency, the majority (61.0–64.9%) of patients
in South Africa, Germany and Poland had symptoms on
at least five days in the previous week, as did approxi-
mately half of patients in Hungary (47.1%) and Spain
(48.4%). In Italy, the majority (53.7%) of patients had
symptoms on 3 to 4 days in the previous week.
Psychometric evaluation
Reliability
Cronbach's alpha scores ranged from 0.43 (Abdominal
pain, German version) to 0.87 (Constipation, Polish ver-
sion) for the GSRS, and from 0.79 (Vitality, Afrikaans ver-
sion) to 0.95 (Emotional distress, Spanish version) for the
QOLRAD (Table 2). Scores were high (range: 0.72–0.87)
for all language versions of the GSRS in the Indigestion,
Diarrhoea and Constipation domains, thus demonstrat-
ing high internal consistency. Scores in the Reflux domain
were also high for the German (0.72), Hungarian (0.73)
and Italian (0.84) versions of the GSRS, but were below
0.7 for the Afrikaans, Polish and Spanish versions. Scores
in the Abdominal pain domain were below 0.7 for all six
countries. For the QOLRAD, Cronbach's alpha scores
were high for all language versions in all domains.
Intraclass correlation coefficients for the two visits spaced
about 1 week apart ranged from 0.36 (Abdominal pain,
German version) to 0.75 (Indigestion, Hungarian and
Spanish versions) for the GSRS, and from 0.41 (Vitality,Page 4 of 12
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sion) for the QOLRAD (Table 3). Intraclass correlation
coefficients were high (> 0.7) for the Hungarian, Polish
and Spanish versions of the GSRS in the Indigestion
domain, for the Hungarian version in the Diarrhoea
domain, and for the Afrikaans, Hungarian, Polish and
Spanish versions in the Constipation domain. Intraclass
correlation coefficients for the GSRS Reflux and Abdomi-
nal pain domains were below 0.7 for all countries. For the
QOLRAD, intraclass correlation coefficients were high for
all domains in the Hungarian version, and for all domains
except Food/drink problems in the German version. Intra-
class correlation coefficients were below 0.7 for all QOL-
RAD domains in the Afrikaans and Polish versions, and
for all but one (Food/drink problems) domain in the
Spanish version. Test-retest reliability was not assessed in
Italy, as a follow-up with the physicians revealed that
many patients were not in a stable phase between visits 1
and 2: some patients changed their self-medication
between the two visits, and some were endoscoped.
Table 1: Patient demographics and clinical data for all countries (total N = 853). Values are in percentages unless otherwise specified.
Variables South Africa Germany Hungary Italy Poland Spain
Number of patients
visit 1 111 141 136 175 135 155
visit 2 54 54 82 101 78 72
Mean age (years), (SD) 42.2 (11.8) 43.8 (14.9) 45.1 (14.2) 45.8 (15.4) 45.0 (14.0) 48.3 (15.9)
Female 68.5 68.8 72.1 61.1 66.7 67.7
Caucasian 11 98 100 100 100 100
Married 59.5 61.7 69.1 69.7 65.9 69.0
Full-time employed 41.4 61.0 64.0 48.6 52.6 43.9
Duration of current episode of dyspepsia symptoms > 1 month 71.2 53.2 72.8 58.3 65.1 72.3
Duration of disease > 5 years 26.1 41.8 24.3 19.4 40.0 49.7
Severity of symptoms last 7 days at least moderate 95.5 89.3 73.5 75.4 77.8 69.7
Symptoms on at least 5 days in previous week 64.9 61.0 47.1 28.6 62.2 48.4
No comorbidity 59.4 80.8 69.8 84.0 73.3 31.6
Concomitant medication
No current medication 33.3 71.6 37.5 58.3 39.2 33.5
Proton pump inhibitors 21.6 15.6 25.7 6.8 27.4 20.6
Predominant dyspepsia symptom
Abdominal pain 70.3 50.4 58.8 38.3 47.4 20.6
Abdominal discomfort 29.7 46.1 30.1 58.3 51.9 79.4
Previous peptic ulcer and/or ulcerative reflux esophagitis 14.4 4.3 6.6 9.1 8.1 5.2
Emotional problems, past 5 years 33.3 2.8 5.1 8.0 13.3 38.7
SD, standard deviation.
Table 2: Cronbach's alpha at visit 1.
Translation
Questionnaire and domain Afrikaans German Hungarian Italian Polish Spanish
GSRS (N = 108) (N = 132) (N = 124) (N = 165) (N = 134) (N = 154)
Reflux 0.61 0.72 0.73 0.84 0.49 0.67
Abdominal pain 0.60 0.43 0.59 0.65 0.49 0.45
Indigestion 0.76 0.79 0.74 0.74 0.73 0.78
Diarrhoea 0.75 0.84 0.79 0.72 0.78 0.82
Constipation 0.82 0.81 0.79 0.76 0.87 0.75
QOLRAD (N = 108) (N = 123) (N = 124) (N = 174) (N = 134) (N = 154)
Emotional distress 0.91 0.94 0.94 0.93 0.92 0.95
Food/drink problems 0.83 0.90 0.90 0.88 0.86 0.91
Physical/social functioning 0.84 0.90 0.89 0.89 0.86 0.91
Sleep disturbance 0.88 0.89 0.94 0.89 0.91 0.93
Vitality 0.79 0.90 0.87 0.80 0.87 0.89
GSRS, Gastrointestinal Symptom Rating Scale; QOLRAD, Quality of Life in Reflux and Dyspepsia questionnaire.Page 5 of 12
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Correlation of the GSRS with the QOLRAD
In the Afrikaans versions, correlations (as defined by a
Pearson's product moment correlation = 0.3) were only
observed between the GSRS Abdominal pain domain and
the QOLRAD Emotional distress and Physical/social func-
tioning domains. In the German versions, the GSRS
Abdominal pain and Indigestion domains correlated with
all QOLRAD domains, but the GSRS Reflux domain cor-
related only with the QOLRAD Food/drink problems
domain. The relevant GSRS domains Reflux, Abdominal
pain and Indigestion correlated with all QOLRAD
domains in the Hungarian version of the questionnaires.
This was also the case for the Italian versions of the ques-
tionnaires, with the exception of the GSRS Reflux and
Indigestion domains, which did not correlate with the
QOLRAD Food/drink problems domain. In the Polish
versions of the questionnaires, the GSRS Reflux and
Abdominal pain domains correlated with the QOLRAD
Food/drink problems, Physical/social functioning, and
Sleep disturbance domains. As was the case with the Ital-
ian versions, the GSRS Reflux, Abdominal pain and Indi-
gestion domains correlated with all QOLRAD domains in
the Spanish version of the questionnaires.
Correlation of the GSRS with the SF-36
Each domain of the GSRS correlated negatively with each
domain of the SF-36 in all language versions of the ques-
tionnaires. Significant correlations between GSRS
domains and SF-36 domains (Pearson's product moment
correlation = 0.3) are shown in Table 4.
Correlation of the QOLRAD with the SF-36
QOLRAD domains correlated significantly with the
majority of SF-36 domains in most language versions. Sig-
nificant correlations between QOLRAD domains and SF-
36 domains (Pearson's product moment correlation =
0.3) are shown in Table 4.
Correlation of the GSRS with the HAD
Correlations between GSRS domains and the HAD anxi-
ety and depression scores are shown in Table 5. The GSRS
Abdominal pain and Indigestion domains correlated sig-
nificantly with the HAD anxiety score in the German,
Spanish and Hungarian populations. The GSRS Reflux
domain correlated with the HAD depression score only in
the Hungarian population. (Note: HAD was not assessed
in South Africa.)
Correlation of the QOLRAD with the HAD
Correlations between QOLRAD domains and the HAD
anxiety and depression scores are shown in Table 5. All
QOLRAD domains correlated with the HAD anxiety
scores in the Hungarian, Italian and Spanish versions of
the questionnaire, and all except Sleep disturbance corre-
lated with the HAD anxiety scores in the German and
Polish versions. Furthermore, all QOLRAD domains cor-
related with the HAD depression scores in the Italian and
Hungarian versions of the questionnaire, and all except
Food/drink problems correlated with the HAD depression
score in the Spanish version.
Correlation of the GSRS with physician-assessed severity of 
symptoms
The relevant GSRS Abdominal pain domain correlated
significantly with physician-assessed severity of symp-
Table 3: Test-retest reliability (intraclass correlation coefficient [ICC]) for Gastrointestinal Symptom Rating Scale (GSRS) and Quality 
of Life in Reflux and Dyspepsia questionnaire (QOLRAD) domains between visits 1 and 2.
Questionnaire and domain Translation
Afrikaans German Hungarian Italian* Polish Spanish
GSRS (N = 108) (N = 132) (N = 124) (N = 165) (N = 134) (N = 154)
Reflux 0.37 0.66 0.59 N/A 0.61 0.48
Abdominal pain 0.55 0.36 0.57 N/A 0.45 0.62
Indigestion 0.46 0.61 0.75 N/A 0.71 0.75
Diarrhoea 0.56 0.67 0.70 N/A 0.63 0.38
Constipation 0.71 0.60 0.72 N/A 0.72 0.72
QOLRAD (N = 108) (N = 123) (N = 124) (N = 174) (N = 134) (N = 154)
Emotional distress 0.51 0.75 0.70 N/A 0.56 0.65
Food/drink problems 0.51 0.62 0.79 N/A 0.62 0.75
Physical/social functioning 0.53 0.73 0.74 N/A 0.68 0.69
Sleep disturbance 0.62 0.73 0.82 N/A 0.61 0.66
Vitality 0.46 0.71 0.74 N/A 0.41 0.66
*In the Italian translation, test-retest reliability was not analyzed because the patients were not in a stable phase between visit 1 and 2.Page 6 of 12
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Abdominal pain and Indigestion domains correlated sig-
nificantly with physician-assessed severity of symptoms in
the Spanish version of the questionnaire, and with physi-
Table 4: Significant correlations between Gastrointestinal Symptom Rating Scale (GSRS), Quality of Life in Reflux and Dyspepsia 
Questionnaire (QOLRAD) and 36-item Short-Form Health Survey (SF-36) domains (Pearson's product moment correlation ≥ 3).
Questionnaire 
and domain
SF-36 domain and correlation coefficient
Afrikaans* German Hungarian Italian Polish Spanish
GSRS
Reflux -- GH (0.32), PF 
(0.30)
BP (0.35), GH 
(0.41), MH (0.38), 
PF (0.46), RP 
(0.30), SF (0.34), V 
(0.39)
-- -- BP (0.35)
Abdominal pain BP (0.45), PF 
(0.33)
BP (0.40), MH 
(0.45), PF (0.34), 
RE (0.36), RP 
(0.43), SF (0.31), V 
(0.40)
BP (0.54), GH 
(0.32), MH (0.45), 
PF (0.43), RE 
(0.30), RP (0.46), 
SF (0.50), V (0.52)
BP (0.43), MH 
(0.36), RE (0.36), 
SF (0.37)
BP (0.36), RP 
(0.35)
BP (0.37), MH 
(0.40), RE (0.34), 
SF (0.35), V (0.34)
Indigestion BP (0.39), PF 
(0.34)
GH (0.35), RE 
(0.31), V (0.30)
BP (0.53), GH 
(0.35), MH (0.42), 
PF (0.43), RE 
(0.30), RP (0.42), 
SF (0.47), V (0.44)
MH (0.30), RE 
(0.31), SF (0.33),
-- BP (0.39), GH 
(0.32), MH (0.32), 
V (0.31)
Diarrhoea -- GH (0.37), MH 
(0.35), PF (0.31), 
RE (0.30), SF 
(0.43)
GH (0.31), SF 
(0.37)
PF (0.30) -- GH (0.31), MH 
(0.37), SF (0.30)
Constipation BP (0.34) SF (0.35) BP (0.40), GH 
(0.41), MH (0.34), 
PF (0.46), RP 
(0.38), SF (0.40), V 
(0.33)
PF (0.39) -- BP (0.30)
QOLRAD
Emotional distress BP (0.50), MH 
(0.35), RE (0.35), 
RP (0.43), SF 
(0.36), V (0.39)
BP (0.41), GH 
(0.40), MH (0.68), 
PF (0.48), RE 
(0.42), RP (0.60), 
SF (0.61), V (0.60)
BP (0.68), GH 
(0.59), MH (0.65), 
PF (0.52), RE 
(0.47), RP (0.55), 
SF (0.58), V (0.68)
BP (0.45), GH 
(0.49), MH (0.59), 
PF (0.36), RE 
(0.49), RP (0.47), 
SF (0.56), V (0.56)
BP (0.42), GH 
(0.36), MH (0.47), 
PF (0.34), RE 
(0.30), RP (0.37), 
SF (0.49), V (0.44)
BP (0.47), GH 
(0.43), MH (0.55), 
PF (0.33), RE 
(0.39), RP (0.42), 
SF (0.51), V (0.44)
Sleep disturbance BP (0.39), GH 
(0.31), MH (0.35), 
RE (0.31), RP 
(0.41), SF (0.38), V 
(0.49)
BP (0.43), GH 
(0.30), MH (0.44), 
PF (0.48), RE 
(0.42), RP (0.60), 
SF (0.61), V (0.60)
BP (0.63), GH 
(0.56), MH (0.51), 
PF (0.64), RE 
(0.51), RP (0.64), 
SF (0.49), V (0.59)
BP (0.46), GH 
(0.48), MH (0.46), 
PF (0.37), RE 
(0.47), RP (0.43), 
SF (0.51), V (0.50)
BP (0.43), MH 
(0.33), PF (0.32), 
RE (0.30), RP 
(0.41), SF (0.38), V 
(0.36)
BP (0.39), GH 
(0.34), MH (0.50), 
PF (0.37), RE 
(0.33), RP (0.44), 
SF (0.44), V (0.47)
Food/drink 
problems
BP (0.32), GH 
(0.31), V (0.41)
BP (0.46), GH 
(0.31), MH (0.50), 
PF (0.50), RE 
(0.42), RP (0.60), 
SF (0.45), V (0.48)
BP (0.62), GH 
(0.40), MH (0.44), 
PF (0.49), RE 
(0.43), RP (0.58), 
SF (0.49), V (0.49)
BP (0.59), GH 
(0.50), MH (0.46), 
RE (0.45), RP 
(0.46), SF (0.52), V 
(0.51)
BP (0.40), GH 
(0.31), MH (0.37), 
PF (0.33), RE 
(0.33), RP (0.40), 
SF (0.41), V (0.32)
BP (0.38), MH 
(0.37), RE (0.37), 
RP (0.35), SF 
(0.39), V (0.33)
Physical/social 
functioning
BP (0.44), MH 
(0.39), PF (0.32), 
RE (0.44), RP 
(0.47), SF (0.48), V 
(0.39)
BP (0.49), GH 
(0.38), MH (0.56), 
PF (0.62), RE 
(0.43), RP (0.69), 
SF (0.64), V (0.52)
BP (0.76), GH 
(0.52), MH (0.61), 
PF (0.66), RE 
(0.54), RP (0.73), 
SF (0.69), V (0.68)
BP (0.58), GH 
(0.49), MH (0.51), 
PF (0.45), RE 
(0.56), RP (0.60), 
SF (0.69), V (0.56)
BP (0.45), GH 
(0.46), MH (0.50), 
PF (0.46), RE 
(0.40), RP (0.53), 
SF (0.55), V (0.42)
BP (0.46), GH 
(0.45), MH (0.48), 
PF (0.49), RE 
(0.35), RP (0.55), 
SF (0.61), V (0.46)
Vitality BP (0.46), MH 
(0.32), RE (0.31), 
RP (0.35), SF 
(0.34), V (0.36)
BP (0.50), GH 
(0.31), MH (0.59), 
PF (0.46), RE 
(0.47), RP (0.66), 
SF (0.49), V (0.63)
BP (0.72), GH 
(0.55), MH (0.63), 
PF (0.60), RE 
(0.51), RP (0.65), 
SF (0.60), V (0.71)
BP (0.54), GH 
(0.47), MH (0.50), 
PF (0.33), RE 
(0.52), RP (0.49), 
SF (0.53), V (0.59)
BP (0.41), GH 
(0.35), MH (0.44), 
PF (0.27), RE 
(0.26), RP (0.40), 
SF (0.50), V (0.44)
BP (0.43), GH 
(0.39), MH (0.52), 
PF (0.36), RE 
(0.38), RP (0.44), 
SF (0.51)
BP, Bodily pain; GH, General Health; MH, Mental Health; PF, Physical functioning; RE, Role – Emotional; RP, Role – Physical; SF, Social Functioning; 
V, VitalityPage 7 of 12
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sion. Taken together, these correlations show convergent
validity.
Correlation of the QOLRAD with physician-assessed severity of 
symptoms
All QOLRAD domains correlated with physician-assessed
severity and frequency of symptoms in the Hungarian ver-
sion of the questionnaire, and all domains except Sleep
disturbance correlated with physician-assessed severity
and frequency in the Spanish version. In the German ver-
sions, the QOLRAD emotional distress domain correlated
with physician-assessed frequency of symptoms, and the
QOLRAD Sleep disturbance domain correlated with phy-
sician-assessed severity. The QOLRAD Vitality domain
correlated with physician-assessed severity in the Italian
version of the questionnaire. In the Polish version, the
QOLRAD Physical/social functioning and Vitality
domains correlated with physician-assessed frequency
and severity of symptoms, and the QOLRAD Emotional
distress domain correlated with physician-assessed fre-
quency of symptoms.
Known-groups validity of the GSRS and the QOLRAD
All domains of the GSRS and the QOLRAD questionnaires
were able to differentiate between groups of patients
whose health status differed according to the physician-
assessed overall frequency and severity of dyspepsia symp-
toms, thereby confirming the known-groups validity of
the instruments. GSRS scores increased with increasing
frequency and severity of dyspepsia symptoms, while
QOLRAD scores decreased with increasing frequency and
severity of symptoms (representing a decrease in daily
functioning) (results not shown).
Discussion
The GSRS and the QOLRAD are two of the most estab-
lished, validated, reliable and responsive disease-specific
instruments available for assessing gastrointestinal symp-
toms and their impact on patients' daily functioning
[37,39]. Both questionnaires have been proven to have
very good psychometric characteristics when tested in
clinical trials in patients with GERD and dyspepsia
[20,56,57]. This paper documents the psychometric vali-
dation of the Afrikaans, German, Hungarian, Italian,
Polish and Spanish translations of the GSRS and the QOL-
RAD in patients with dyspepsia. The study was conducted
Table 5: Pearson's product moment correlations between Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux 
and Dyspepsia Questionnaire (QOLRAD) domains and Hospital Anxiety and Depression Scale (HAD).
Questionnaire and domain Translation
Afrikaans* German Hungarian Italian Polish Spanish
GSRS (N = 108) (N = 132) (N = 124) (N = 165) (N = 134) (N = 154)
Reflux N/A A: 0.29, A: 0.44, A: 0.16 A: 0.22 A: 0.15
D: 0.14 D: 0.44 D: 0.01 D: 0.04 D: 0.17
Abdominal pain N/A A: 0.48, A: 0.38, A: 0.29 A: 0.15 A: 0.35
D: 0.18 D: 0.38 D: 0.18 D: 0.03 D: 0.28
Indigestion N/A A: 0.44, A: 0.38, A: 0.27 A: 0.09 A: 0.33
D: 0.14 D: 0.36 D: 0.15 D: 0.13 D: 0.25
Diarrhoea N/A A: 0.35, A: 0.26, A: 0.10 A: 0.24 A: 0.31
D: 0.21 D: 0.19 D: -0.01 D: 0.21 D: 0.26
Constipation N/A A: 0.32, A: 0.39, A: 0.25 A: -0.00 A: 0.25
D: 0.07 D: 0.48 D: 0.11 D: -0.01 D: 0.16
QOLRAD (N = 108) (N = 123) (N = 124) (N = 174) (N = 134) (N = 154)
Emotional distress N/A A: 0.49, A: 0.67, A: 0.67 A: 0.40 A: 0.41
D: 0.36 D: 0.57 D: 0.49 D: 0.34 D: 0.44
Food/drink problems N/A A: 0.35, A: 0.48, A: 0.51 A: 0.35 A: 0.30
D: 0.18 D: 0.47 D: 0.47 D: 0.27 D: 0.28
Physical/social functioning N/A A: 0.36, A: 0.60, A: 0.64 A: 0.43 A: 0.37
D: 0.28 D: 0.64 D: 0.53 D: 0.38 D: 0.48
Sleep disturbance N/A A: 0.29, A: 0.59, A: 0.53 A: 0.29 A: 0.39
D: 0.14 D: 0.59 D: 0.41 D: 0.27 D: 0.36
Vitality N/A A: 0.41, A: 0.64, A: 0.59 A: 0.30 A: 0.43
D: 0.32 D: 0.61 D: 0.46 D: 0.30 D: 0.42
*The HAD was not used in South Africa. A = HAD anxiety score; D = HAD depression score. Strong correlation, > 0.60; moderate correlation, 
0.30–0.60; low (very low) correlation, < 0.30.Page 8 of 12
(page number not for citation purposes)
Health and Quality of Life Outcomes 2008, 6:12 http://www.hqlo.com/content/6/1/12mainly in gastroenterology centres and, therefore, results
are particular to patients referred for gastroenterological
investigation. Because of the standardized methodology
used, results from all countries are directly comparable.
Questionnaires were completed in an electronic data cap-
ture device (ECD), which ensures that all questions are
answered in full. Although ECD technology is becoming
an increasing part of clinical trials, it is not yet widely
available, and certainly not that widespread in clinical
practice. Thus, in South Africa, paper versions of the ques-
tionnaires were used for the present study, and this may
have affected the results obtained in this country, espe-
cially as the use of ECD technology has been shown to
increase patient compliance and improve the quality of
the data [36].
The demographic and clinical characteristics of the patient
populations were comparable in the different countries
studied in terms of the number of patients recruited, their
age, gender, symptom status and medication use. The Afri-
kaans patient population had the highest incidence of
abdominal pain as the predominant dyspeptic symptom
as well as the highest proportion of patients with a history
of previous peptic ulcer and/or ulcerative reflux esophagi-
tis. This was probably due to the fact that all South African
subjects were recruited from a single gastroenterology
clinic in a healthcare system that may refer only the most
severely affected patients.
In terms of psychometric characteristics, internal consist-
ency was high in all domains of all language versions of
the QOLRAD, thus supporting construct validity. Internal
consistency was also high in the Indigestion, Diarrhoea
and Constipation domains of the GSRS in all language
versions. However, although abdominal pain is the typi-
cal dyspepsia symptom, internal consistency was only
moderate in the Abdominal pain domain of the GSRS.
This generally low internal consistency in the Abdominal
pain domain probably reflects the difficulty of measuring
this often fluctuating symptom, as well as the fact that the
GSRS Abdominal pain domain contains only two items.
In previous international studies conducted in patients
with GERD, internal consistency also tended to be lower
in the Abdominal pain domain of the GSRS than in its
other domains [30-35].
Test-retest reliability was good for most or all domains in
the Hungarian and German translations of the QOLRAD,
but only for one domain in the Spanish version and for no
domains in the Afrikaans and Polish versions of the QOL-
RAD. It is not clear why the test-retest reliability was low
in these patient populations, although it may be an indi-
cation that the frequency, severity and impact of abdomi-
nal symptoms were not as stable on a week-to-week basis
in these patients as was estimated by the investigators. No
test-retest was performed in Italy, so it was not possible to
assess test-retest reliability for the Italian version of the
QOLRAD. Previous international studies in patients with
GERD have yielded acceptable test-retest reliability for the
German (ICC: 0.70–0.84), Spanish (ICC: 0.79–0.85) and
Afrikaans (ICC: 0.71–0.82) versions of the QOLRAD, but
only for some domains of the Polish version (ICC: 0.51–
74) of the QOLRAD [30-35]. In the GSRS, test-retest relia-
bility was acceptable in the Indigestion and Constipation
domains in most language versions. However, reliability
was lower in the Abdominal pain domains in all countries
assessed. As with internal consistency, the generally low
test-retest reliability in the Abdominal pain domain is
most likely due to the GSRS Abdominal pain domain con-
taining only two items, as well as the complexity of meas-
uring this variable symptom. It is also likely that at least
some of the patients deemed stable by the physicians
experienced small changes in their symptoms that were
picked up by the PROs.
In terms of construct validity, all GSRS domains correlated
with all QOLRAD domains. Correlation was significant
for the relevant GSRS Abdominal pain domain and most
or all QOLRAD domains in the majority of the different
language versions. The GSRS Abdominal pain domain
also correlated significantly with the relevant SF-36 Bodily
pain domain in all language versions. All QOLRAD
domains correlated significantly with the majority of SF-
36 domains in most language versions. Both the GSRS
and the QOLRAD were able to differentiate between
patients whose health status differed with regard to fre-
quency and severity of symptoms, thereby confirming the
known-groups validity of the instruments. Known-groups
validity has also been confirmed for several translations of
the GSRS and the QOLRAD in patients with GERD [30-
32,35]. Confirmatory factor analysis has been shown to
support the validity of the Scandinavian language versions
of the GSRS and the QOLRAD in patients with GERD
[41]. Future studies could use this approach to further
assess the validity of the additional language versions pre-
sented here.
The relevant GSRS Abdominal pain domain correlated
with the HAD anxiety score in most of the language ver-
sions assessed, and most of the QOLRAD domains corre-
lated with the HAD anxiety score in all language versions
assessed. Dyspepsia tends to be associated with anxiety
and depression [58]. Previous reports are somewhat con-
tradictory on the role of psychological morbidity in dys-
pepsia symptoms and healthcare-seeking behaviour
[1,58], suggesting that additional research is required on
this potentially important aspect of the disorder.Page 9 of 12
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reported symptoms with those assessed by the physician,
correlations were only low to moderate. These discrepan-
cies in patient-reported and observer-reported symptom
status have been well-documented [59-61]. Our view is
that the physician examination needs to be balanced with
the patient-reported symptom status when deciding on
patient management and outcomes [39,62].
In summary, all language versions of the QOLRAD
showed good internal consistency and reliability,
although only the German and Hungarian translations
were able to demonstrate acceptable test-retest reliability.
In general, all language versions of the GSRS were reliable
and showed good internal consistency for the Indigestion,
Diarrhoea and Constipation domains, but not for the
Abdominal pain domain. Overall, the test-retest reliability
of the GSRS was not acceptable.
Conclusion
In conclusion, the German, Hungarian, Italian, Polish,
Spanish and Afrikaans versions of GSRS and QOLRAD are
reliable and show good internal consistency for use in
clinical trials. However, the test-retest reliability was low
in most language versions. By evaluating symptoms and
their impact on patients' lives, both these instruments
help physicians interpret clinical benefits as outcomes of
significance to patients. We believe that these results will
further facilitate the use of these instruments in the clini-
cal setting.
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